Bayer is looking into future options for the established drugs business, partly because of price pressure in China, the German company’s head of pharmaceuticals said.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Astellas and Amgen will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients’ out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications.
GlaxoSmithKline veteran Richard Saynor is coming home to Sandoz after being named the new chief executive officer of the Novartis subsidiary.
Novartis raised the company’s 2019 profit target, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval in May 2019.
Start Codon launched in Cambridge, England with funding from keystone investors including Cambridge Innovation Capital, Babraham Bioscience Technologies, Genentech, Jonathan Milner and Ian Tomlinson.
Lilly inked a deal with Eddingpharm for the rights to two legacy antibiotic medicines and a manufacturing facility in Suzhou, China.
Nocion Therapeutics launched in Cambridge, Mass., with a $27 million series A raise this week.
Privately held Talaris Therapeutics secured $100 million in a Series A financing round as the company undergoes a rebranding with a new leadership team.
With a $75 million infusion of new financing, Massachusetts-based Arrakis Therapeutics will focus the company’s pipeline on oncology and genetically validated targets in other diseases.
Gilead Sciences Inc. will partner with privately held insitro to develop therapies for a fatty liver disease called NASH.